KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD

KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc. KONEF, has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelics subsidiary of Creso Pharma COPHF developing phase 2 clinical trials to test the efficacy of psilocybin on treatment-resistant post traumatic stress disorder (PTSD).

The deal involves KGK performing research services, including the development of the clinical trial protocol, preparations towards the phase 2 trials, data management and validation, statistical analysis and drafting of the final report.

Creso Pharma usually works with cannabis, bringing pharmaceutical expertise and methodological rigor to their high-quality, GMP products, offering from cannabis to hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health.

For its part, Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics. Its subsidiary KGK is a North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products since 1997. 

As Wellbeing and KGK’s CEO Najla Guthrie stated: “Over the past 25 years, we have successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets. This marks an important step in moving the industry that much closer to creating alternative medicines for a growing population base.”

On his behalf, Halucenex CEO and founder Bill Flemming added: “KGK is a leading contract research organization, offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries. We are confident that KGK’s role will enable us to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions.”

Photo Courtesy of Geralt Sergei Tokmakov on Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsContractsMarketsBill FlemmingKGK ScienceNajla Guthrie Halucenex Life Sciences
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.